topwatch - we pay attention
× Bifeprunox
Make use of our vast resources on Bifeprunox to build up your know-how on Bifeprunox. Only after reading this article will you realize the mettle of Bifeprunox. In May of 2007 pharmaceutical companies Wyeth Solvay and psychiatric research company Lundbeck reported more recent findings on bifeprunox a possible new drug for treating schizophrenia that has been in the works for some time now. We hope that through reading of this article on Bifeprunox, interest in Bifeprunox is once again activated.
Related stories from the web
Lessons from a Big Pharma downfall (CNN Money)
Wyeth's recent announcement that chief operating officer Bernard Poussot would be taking over as CEO was abrupt and unceremonious. But the unexpected departure of Bob Essner, who will soon turn 60, signaled the end of an era at the country's fifth-largest pharmaceutical company.
CORRECTED: Wyeth names Poussot CEO, boosts buybacks (Reuters via Yahoo! News)
(In paragraph 7, corrects to show bifeprunox is a schizophrenia drug, not a depression drug)
Wyeths ratings confirmed outlook positive - Moody's (Sharewatch)
MUMBAI (Thomson Financial) - Moody's Investors Service said it confirmed Wyeth's ratings, including its 'A3' senior unsecured long-term rating and its 'P-2' commercial paper rating, reflecting the company's strong operating profile and its good financial metrics.
